 Nicole Curci
Concepts (133)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 12 | 2022 | 400 | 2.450 |
Why?
| | Carcinoma, Renal Cell | 7 | 2022 | 214 | 1.830 |
Why?
| | Prostatic Neoplasms | 8 | 2023 | 1031 | 1.270 |
Why?
| | Magnetic Resonance Imaging | 11 | 2023 | 3566 | 0.920 |
Why?
| | Aneurysm | 2 | 2012 | 31 | 0.760 |
Why?
| | Femoral Vein | 2 | 2012 | 34 | 0.760 |
Why?
| | Catheter Ablation | 2 | 2022 | 349 | 0.680 |
Why?
| | Venous Thrombosis | 2 | 2012 | 186 | 0.660 |
Why?
| | Tomography, X-Ray Computed | 11 | 2024 | 2677 | 0.650 |
Why?
| | Embolization, Therapeutic | 2 | 2012 | 229 | 0.640 |
Why?
| | Prostate | 4 | 2018 | 175 | 0.620 |
Why?
| | Watchful Waiting | 1 | 2018 | 80 | 0.560 |
Why?
| | Kidney Diseases, Cystic | 3 | 2021 | 24 | 0.540 |
Why?
| | Radiology | 4 | 2021 | 181 | 0.510 |
Why?
| | Quality Assurance, Health Care | 1 | 2018 | 322 | 0.510 |
Why?
| | Pulmonary Artery | 2 | 2012 | 1082 | 0.500 |
Why?
| | Ovarian Neoplasms | 3 | 2024 | 563 | 0.390 |
Why?
| | Bezoars | 1 | 2011 | 4 | 0.370 |
Why?
| | Intussusception | 1 | 2011 | 28 | 0.370 |
Why?
| | Pneumonectomy | 1 | 2012 | 154 | 0.340 |
Why?
| | Immunosuppressive Agents | 2 | 2012 | 890 | 0.330 |
Why?
| | Intestine, Small | 1 | 2011 | 154 | 0.330 |
Why?
| | Radiology Information Systems | 2 | 2018 | 29 | 0.290 |
Why?
| | Ultrasonography | 3 | 2023 | 751 | 0.290 |
Why?
| | Biopsy | 4 | 2023 | 1126 | 0.280 |
Why?
| | Teaching | 2 | 2018 | 226 | 0.250 |
Why?
| | Retrospective Studies | 14 | 2024 | 15564 | 0.250 |
Why?
| | Neoplasm Grading | 3 | 2024 | 306 | 0.220 |
Why?
| | Microwaves | 2 | 2022 | 37 | 0.220 |
Why?
| | Ovarian Diseases | 1 | 2023 | 12 | 0.210 |
Why?
| | Humans | 31 | 2024 | 136783 | 0.210 |
Why?
| | Magnetic Resonance Imaging, Interventional | 1 | 2023 | 24 | 0.210 |
Why?
| | Kidney | 6 | 2021 | 1463 | 0.200 |
Why?
| | Aged | 9 | 2024 | 23729 | 0.200 |
Why?
| | Cysts | 1 | 2023 | 111 | 0.190 |
Why?
| | Prostatectomy | 2 | 2022 | 104 | 0.190 |
Why?
| | Peritoneal Neoplasms | 1 | 2022 | 94 | 0.180 |
Why?
| | Angiography | 2 | 2012 | 207 | 0.180 |
Why?
| | Neoadjuvant Therapy | 1 | 2024 | 403 | 0.180 |
Why?
| | Syndrome | 2 | 2012 | 357 | 0.180 |
Why?
| | Salpingo-oophorectomy | 1 | 2020 | 18 | 0.170 |
Why?
| | Contrast Media | 2 | 2021 | 462 | 0.170 |
Why?
| | Diagnosis, Differential | 3 | 2021 | 1483 | 0.170 |
Why?
| | Robotic Surgical Procedures | 1 | 2022 | 126 | 0.170 |
Why?
| | Interdisciplinary Placement | 1 | 2019 | 2 | 0.160 |
Why?
| | Pelvic Neoplasms | 1 | 2020 | 26 | 0.160 |
Why?
| | Incidental Findings | 1 | 2020 | 87 | 0.160 |
Why?
| | Biliary Tract Neoplasms | 1 | 2020 | 30 | 0.160 |
Why?
| | Multidetector Computed Tomography | 1 | 2019 | 39 | 0.160 |
Why?
| | Middle Aged | 11 | 2024 | 33200 | 0.150 |
Why?
| | Treatment Outcome | 5 | 2024 | 10764 | 0.150 |
Why?
| | Teacher Training | 1 | 2018 | 6 | 0.150 |
Why?
| | Radiography, Abdominal | 1 | 2018 | 45 | 0.150 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2019 | 89 | 0.140 |
Why?
| | Education, Medical, Continuing | 1 | 2018 | 125 | 0.140 |
Why?
| | Glomerular Filtration Rate | 1 | 2021 | 744 | 0.130 |
Why?
| | Mentoring | 1 | 2019 | 143 | 0.130 |
Why?
| | Disease Progression | 1 | 2024 | 2750 | 0.130 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 451 | 0.120 |
Why?
| | Radiography | 1 | 2018 | 829 | 0.120 |
Why?
| | Risk Assessment | 2 | 2018 | 3429 | 0.120 |
Why?
| | Male | 13 | 2023 | 67361 | 0.120 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2018 | 256 | 0.120 |
Why?
| | Education, Medical | 1 | 2018 | 260 | 0.110 |
Why?
| | Adipose Tissue | 1 | 2019 | 629 | 0.110 |
Why?
| | Machine Learning | 1 | 2019 | 487 | 0.110 |
Why?
| | Reproducibility of Results | 2 | 2018 | 3272 | 0.100 |
Why?
| | Follow-Up Studies | 2 | 2012 | 5115 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2030 | 0.100 |
Why?
| | Transcriptome | 1 | 2018 | 971 | 0.100 |
Why?
| | Prunus | 1 | 2011 | 2 | 0.090 |
Why?
| | Female | 11 | 2024 | 72840 | 0.090 |
Why?
| | Abdomen, Acute | 1 | 2011 | 21 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1942 | 0.090 |
Why?
| | Rare Diseases | 1 | 2012 | 101 | 0.090 |
Why?
| | Vena Cava Filters | 1 | 2012 | 61 | 0.090 |
Why?
| | Internship and Residency | 2 | 2018 | 1131 | 0.090 |
Why?
| | Prednisone | 1 | 2012 | 243 | 0.090 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2847 | 0.090 |
Why?
| | Prospective Studies | 2 | 2023 | 7583 | 0.080 |
Why?
| | Vascular Surgical Procedures | 1 | 2012 | 299 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2012 | 1235 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2012 | 596 | 0.070 |
Why?
| | Laparoscopy | 1 | 2011 | 464 | 0.070 |
Why?
| | Adult | 5 | 2020 | 37616 | 0.060 |
Why?
| | Societies, Medical | 2 | 2019 | 820 | 0.060 |
Why?
| | CA-125 Antigen | 1 | 2024 | 14 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2831 | 0.050 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2024 | 63 | 0.050 |
Why?
| | Image-Guided Biopsy | 1 | 2023 | 39 | 0.050 |
Why?
| | Torsion Abnormality | 1 | 2023 | 16 | 0.050 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2024 | 75 | 0.050 |
Why?
| | Urologists | 1 | 2023 | 17 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2024 | 390 | 0.050 |
Why?
| | Gallium Isotopes | 1 | 2022 | 1 | 0.050 |
Why?
| | Gallium Radioisotopes | 1 | 2022 | 14 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2022 | 133 | 0.040 |
Why?
| | Algorithms | 2 | 2019 | 1686 | 0.040 |
Why?
| | Radiologists | 1 | 2021 | 50 | 0.040 |
Why?
| | Peer Review | 1 | 2019 | 50 | 0.040 |
Why?
| | Portal Vein | 1 | 2020 | 119 | 0.040 |
Why?
| | Angiomyolipoma | 1 | 2019 | 24 | 0.040 |
Why?
| | Pelvis | 1 | 2020 | 112 | 0.040 |
Why?
| | Cohort Studies | 2 | 2020 | 5718 | 0.040 |
Why?
| | Digital Rectal Examination | 1 | 2018 | 10 | 0.040 |
Why?
| | Faculty | 1 | 2019 | 144 | 0.040 |
Why?
| | Organizational Objectives | 1 | 2018 | 73 | 0.040 |
Why?
| | Artifacts | 1 | 2019 | 129 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2018 | 104 | 0.030 |
Why?
| | Education, Distance | 1 | 2018 | 48 | 0.030 |
Why?
| | Peer Group | 1 | 2019 | 244 | 0.030 |
Why?
| | Prostate-Specific Antigen | 1 | 2018 | 161 | 0.030 |
Why?
| | Carbon | 1 | 2019 | 223 | 0.030 |
Why?
| | Problem-Based Learning | 1 | 2018 | 90 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2019 | 216 | 0.030 |
Why?
| | Adipocytes | 1 | 2019 | 218 | 0.030 |
Why?
| | Needs Assessment | 1 | 2019 | 369 | 0.030 |
Why?
| | Delphi Technique | 1 | 2018 | 273 | 0.030 |
Why?
| | Evidence-Based Practice | 1 | 2018 | 220 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2018 | 318 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 777 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 679 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2023 | 3537 | 0.030 |
Why?
| | Research Design | 1 | 2021 | 1107 | 0.030 |
Why?
| | Learning | 1 | 2018 | 414 | 0.030 |
Why?
| | Gene Expression | 1 | 2018 | 1499 | 0.030 |
Why?
| | Genomics | 1 | 2018 | 790 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2417 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5417 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4018 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 7569 | 0.020 |
Why?
| | Child, Preschool | 1 | 2023 | 11069 | 0.020 |
Why?
| | Child | 1 | 2023 | 21968 | 0.010 |
Why?
|
|
Curci's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|